Sending Email. Hold on just a sec…

Success! Your Email has been sent.

Overview

The CTRC at UTHSCSA has jointly conducted an annual Practical Applications of New Agents conference since 1998. As a National Cancer Institute-designated cancer center, one of only three in the state of Texas, the CTRC is recognized for scientific excellence and extensive resources focused on cancer. CTRC's total patient care system - that consists of breakthrough research, state-of-the-art technology and multidisciplinary clinical care delivered through a team of world-class physicians, laboratory scientists and other medical professional - allows it to seamlessly translate the latest research directly to patients.

Cancer remains a leading cause of death in this country. Educating the healthcare professional about newly available agents in oncology is crucial. The Practical Applications of New Agents in Oncology conference focus is on the large number of new anticancer agents and related supportive therapeutics that have been approved over the last several years, as well as those that will likely be approved. Speakers will discuss the incorporation of these agents into standard clinical practice, providing guidance to front-line clinicians, nurses and pharmacists regarding current or projected appropriate use of these therapeutics. Topics will include both early and late stages of various malignancies, and combined modality therapies (chemotherapy + surgery + radiotherapy) whenever pertinent.

As a result of attending the conference, attendees will be able to cite the results of clinical studies of new anticancer agents and current dilemmas, with a principal focus on discerning the role or eventual role of new therapies in the clinical practice of oncology. They will also be able to describe the procedure for determining incorporation of new anticancer agents and therapeutics into clinical practice.

Program Goals

To provide the most up-to-date treatment and care to patients with cancer, information regarding new agents must be spread to the healthcare professional community. The Practical Applications of New Agents in Oncology conference disseminates this information to the healthcare professional who in turn will use this information to provide the highest quality cancer treatment.

This conference will focus on the large number of new anticancer agents and related supportive therapeutics that have been approved over the last several years, as well as those that will likely be approved. Speakers will discuss the incorporation of these agents into standard clinical practice, providing guidance to front-line clinicians, nurses and pharmacists regarding current or projected appropriate use of these therapeutics.

Educational Objectives

Objectives are statements that clearly describe what the learner will be able to know or do after participating in the CME activity.

• Cite the results of clinical studies of new anticancer agents and current dilemmas, with a principal focus on discerning the role or eventual role of new therapies in the clinical practice of oncology.
• Describe the procedure for determining incorporation of new anticancer agents and therapeutics into clinical practice.
• Discuss management of adverse effects associated with cancer treatment.
• Choose appropriate treatment options for patients with cancer based on clinical data and individual patient characteristics.
• Discuss novel agents in development for the treatment of cancer.

Target Audience

The conference has an attractive format and represents national points of view, making it a stimulating meeting for primary care and oncology clinicians, physicians, nurses, nurse practitioners, physician assistants, other allied health professionals, and students.

Program Committee

Ian Thompson, MD
Course Co-Director
Executive Director
Cancer Therapy   Research Center at UT Health Science Center San Antonio

Monica Mita, MD, MSC
Course Co-Director
Clinical Research Director, IDD
Assistant Professor of Medicine
Cancer Therapy   Research Center at UT Health Science Center San Antonio
Institute for Drug Development

Brenda Johnson, MEd
Director, Continuing Medical Education
UT Health Science Center San Antonio

Anand Karnad, MD
Professor, Hematology and Medical Oncology, Castella
Aging Chair
UT Health Science Center San Antonio

Rich Markow
Symposia Director, Continuing Medical Education
UT Health Science Center San Antonio

Gerardo Medina, RN, OCN, CCRP
Research Nursing Supervisor
Cancer Therapy   Research Center at UT Health Science Center San Antonio
Institute for Drug Development

Alain C. Mita, MD, MSc
Clinical Investigator
Assistant Professor of Medicine
Cancer Therapy   Research Center at UT Health Science Center San Antonio
Institute for Drug Development

Steffan Nawrocki, PhD
Assistant Professor, Med/Hematology   Med Oncology
Cancer Therapy   Research Center at UT Health Science Center San Antonio
Institute for Drug Development

Scott Soefje, PharmD, BCOP
Director of Investigational Drug Section for CTRC
Cancer Therapy   Research Center at UT Health Science Center San Antonio

Rosalie Tierney-Gumaer, BSN, MSN, MPH, CPHQ
Director, Continuing Nursing Education
UT Health Science Center at San Antonio

Yubao Wang, MD, PhD
Assistant Professor, Med/Hematology   Med Oncology
UT Health Science Center San Antonio

Accreditation - CME, CNE

Continuing Medical Education Statements The UT Health Science Center San Antonio School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

UT Health Science Center San Antonio School of Medicine designates this educational activity for a maximum of 7.2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education Statements
The University of Texas Health Science Center at San Antonio, School of Nursing, is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

This activity meets Type I criteria for mandatory continuing education requirements toward relicensure as established by the Texas Board of Nursing. This education program offers up to 9.15 nursing contact hours.